• Ramon Roozendaal, Laura Solforosi, Daniel J Stieh, Jan Serroyen, Roel Straetemans, Anna Dari, Muriel Boulton, Frank Wegmann, Sietske K Rosendahl Huber, Joan E M van der Lubbe, Jenny Hendriks, Mathieu Le Gars, Liesbeth Dekking, Dominika N Czapska-Casey, Nuria Guimera, Sarah Janssen, Sarah Tete, Abishek Chandrashekar, Noe B Mercado, Jingyou Yu, Wouter Koudstaal, Juan J Perez-Ruixo, Jerry Sadoff, Dan H Barouch, Hanneke Schuitemaker, and Roland Zahn.
• Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
• Nat Commun. 2021 Oct 7; 12 (1): 5877.

AbstractSeveral COVID-19 vaccines have recently gained authorization for emergency use. Limited knowledge on duration of immunity and efficacy of these vaccines is currently available. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short-lived, and preliminary evidence indicates waning antibody titers following SARS-CoV-2 infection. In this work, we model the relationship between immunogenicity and protective efficacy of a series of Ad26 vectors encoding stabilized variants of the SARS-CoV-2 Spike protein in rhesus macaques and validate the analyses by challenging macaques 6 months after immunization with the Ad26.COV2.S vaccine candidate that has been selected for clinical development. We show that Ad26.COV2.S confers durable protection against replication of SARS-CoV-2 in the lungs that is predicted by the levels of Spike-binding and neutralizing antibodies, indicating that Ad26.COV2.S could confer durable protection in humans and immunological correlates of protection may enable the prediction of durability of protection.© 2021. The Author(s).

34 keywords...

hide…